PURPOSE: Simultaneous injection of autologous bone marrow cells and skeletal myoblasts has been demonstrated to improve cardiac function in animal models. We evaluated the potential application of this combination cell therapy in patients with severe ischemic cardiomyopathy who required left ventricular assist device (LVAD) implantation. METHODS: Four patients (age range, 43-69 years) who required LVAD implantation due to severe ischemic cardiomyopathy were studied. Skeletal myoblasts were obtained from the thigh, while bone marrow mononuclear cells were collected and purified at the time of the operation. These cells were directly injected in a serial manner into the damaged myocardium. RESULTS: No fatal arrhythmias or major complications were observed. The number of injected skeletal myoblasts ranged from 2.7 × 10(7) to 3.0 × 10(8), and their purity ranged from 25% to 96%. Two patients showed decreased brain natriuretic peptide levels and echocardiographic improvements in the transplanted areas, as well as increased perfusion revealed by H(2) (15)O positron emission tomography, of whom one was successfully weaned from LVAD. Histological findings at autopsy of the other patient showed a small amount of skeletal muscle in the injected area. Only marginal improvements were observed in the other two patients. CONCLUSIONS: Combined cell transplantation is feasible for patients with severe ischemic cardiomyopathy, and functional recovery is anticipated in selected patients.
PURPOSE: Simultaneous injection of autologous bone marrow cells and skeletal myoblasts has been demonstrated to improve cardiac function in animal models. We evaluated the potential application of this combination cell therapy in patients with severe ischemic cardiomyopathy who required left ventricular assist device (LVAD) implantation. METHODS: Four patients (age range, 43-69 years) who required LVAD implantation due to severe ischemic cardiomyopathy were studied. Skeletal myoblasts were obtained from the thigh, while bone marrow mononuclear cells were collected and purified at the time of the operation. These cells were directly injected in a serial manner into the damaged myocardium. RESULTS: No fatal arrhythmias or major complications were observed. The number of injected skeletal myoblasts ranged from 2.7 × 10(7) to 3.0 × 10(8), and their purity ranged from 25% to 96%. Two patients showed decreased brain natriuretic peptide levels and echocardiographic improvements in the transplanted areas, as well as increased perfusion revealed by H(2) (15)O positron emission tomography, of whom one was successfully weaned from LVAD. Histological findings at autopsy of the other patient showed a small amount of skeletal muscle in the injected area. Only marginal improvements were observed in the other two patients. CONCLUSIONS: Combined cell transplantation is feasible for patients with severe ischemic cardiomyopathy, and functional recovery is anticipated in selected patients.
Authors: H C Ott; N Bonaros; R Marksteiner; D Wolf; E Margreiter; T Schachner; G Laufer; S Hering Journal: Eur J Cardiothorac Surg Date: 2004-04 Impact factor: 4.191
Authors: Gerd P Meyer; Kai C Wollert; Joachim Lotz; Jan Steffens; Peter Lippolt; Stephanie Fichtner; Hartmut Hecker; Arnd Schaefer; Lubomir Arseniev; Bernd Hertenstein; Arnold Ganser; Helmut Drexler Journal: Circulation Date: 2006-03-06 Impact factor: 29.690
Authors: Nabil Dib; Robert E Michler; Francis D Pagani; Susan Wright; Dean J Kereiakes; Rose Lengerich; Philip Binkley; Diane Buchele; Inder Anand; Cory Swingen; Marcelo F Di Carli; James D Thomas; Wael A Jaber; Shaun R Opie; Ann Campbell; Patrick McCarthy; Michael Yeager; Vasken Dilsizian; Bartley P Griffith; Ronald Korn; Steven K Kreuger; Marwan Ghazoul; W Robb MacLellan; Gregg Fonarow; Howard J Eisen; Jonathan Dinsmore; Edward Diethrich Journal: Circulation Date: 2005-09-20 Impact factor: 29.690
Authors: D A Taylor; B Z Atkins; P Hungspreugs; T R Jones; M C Reedy; K A Hutcheson; D D Glower; W E Kraus Journal: Nat Med Date: 1998-08 Impact factor: 53.440
Authors: Philippe Menasché; Ottavio Alfieri; Stefan Janssens; William McKenna; Hermann Reichenspurner; Ludovic Trinquart; Jean-Thomas Vilquin; Jean-Pierre Marolleau; Barbara Seymour; Jérôme Larghero; Stephen Lake; Gilles Chatellier; Scott Solomon; Michel Desnos; Albert A Hagège Journal: Circulation Date: 2008-02-19 Impact factor: 29.690
Authors: Charles E Murry; Mark H Soonpaa; Hans Reinecke; Hidehiro Nakajima; Hisako O Nakajima; Michael Rubart; Kishore B S Pasumarthi; Jitka Ismail Virag; Stephen H Bartelmez; Veronica Poppa; Gillian Bradford; Joshua D Dowell; David A Williams; Loren J Field Journal: Nature Date: 2004-03-21 Impact factor: 49.962
Authors: Marie Crahès; Marie-Cécile Bories; Jean-Thomas Vilquin; Jean-Pierre Marolleau; Michel Desnos; Jérôme Larghero; Gilles Soulat; Patrick Bruneval; Albert A Hagège; Philippe Menasché Journal: Stem Cells Transl Med Date: 2018-09-13 Impact factor: 6.940